Literature DB >> 15129890

A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis.

E McColl1, S W Han, J R Barton, M R Welfare.   

Abstract

The aim of this study was to compare the discriminatory power of a generic and a condition-specific quality of life measure (the Medical Outcomes Study Short-Form 36 (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ)) with respect to sub-groups defined by disease-related and other factors, in a sample of patients with ulcerative colitis. Disease activity was generally more highly correlated with IBDQ scores than with SF-36 scores. The only significant differences with respect to disease extent were in the SF-36 energy/vitality and social function domains. Age was negatively and weakly to moderately correlated with the physical domains of the SF-36 but positively though weakly correlated with scores on the IBDQ emotional domain and those domains of the SF-36 related to mental well-being. Co-existing chronic illness, even on controlling for age, was associated with significantly poorer scores on the generic measure, but had little influence on IBDQ scores. In conclusion, generic and disease-specific measures of quality of life appear to be complementary rather than interchangeable. We recommend the use of both types of measure in parallel.

Entities:  

Mesh:

Year:  2004        PMID: 15129890     DOI: 10.1023/B:QURE.0000021701.28467.57

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  30 in total

Review 1.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

2.  Methods for assessing condition-specific and generic functional status outcomes after total knee replacement.

Authors:  M E Kantz; W J Harris; K Levitsky; J E Ware; A R Davies
Journal:  Med Care       Date:  1992-05       Impact factor: 2.983

3.  Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus".

Authors:  R G Watson; T C Tham; B T Johnston; N I McDougall
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

5.  The inflammatory bowel disease questionnaire: a valid and reliable measure in ulcerative colitis patients in the North East of England.

Authors:  S W Han; E McColl; N Steen; J R Barton; M R Welfare
Journal:  Scand J Gastroenterol       Date:  1998-09       Impact factor: 2.423

6.  Discriminative aspects of two generic and two asthma-specific instruments: relation with symptoms, bronchodilator use and lung function in patients with mild asthma.

Authors:  T van der Molen; D S Postma; A J Schreurs; H E Bosveld; M R Sears; B Meyboom de Jong
Journal:  Qual Life Res       Date:  1997-05       Impact factor: 4.147

7.  Effects of comorbidity on health-related quality-of-life scores: an analysis of clinical trial data.

Authors:  J Xuan; L J Kirchdoerfer; J G Boyer; G J Norwood
Journal:  Clin Ther       Date:  1999-02       Impact factor: 3.393

8.  Monitoring the quality of life in patients with coronary artery disease.

Authors:  J A Spertus; J A Winder; T A Dewhurst; R A Deyo; S D Fihn
Journal:  Am J Cardiol       Date:  1994-12-15       Impact factor: 2.778

9.  Effect sizes for interpreting changes in health status.

Authors:  L E Kazis; J J Anderson; R F Meenan
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

10.  Comparison of generic (SF-36) vs. disease-specific (GERD-HRQL) quality-of-life scales for gastroesophageal reflux disease.

Authors:  V Velanovich
Journal:  J Gastrointest Surg       Date:  1998 Mar-Apr       Impact factor: 3.267

View more
  10 in total

Review 1.  A Systematic Review of Self-Management Interventions for Inflammatory Bowel Disease.

Authors:  Samantha Conley; Nancy Redeker
Journal:  J Nurs Scholarsh       Date:  2016-01-12       Impact factor: 3.176

Review 2.  Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review.

Authors:  Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey
Journal:  Qual Life Res       Date:  2017-08-28       Impact factor: 4.147

3.  Beyond standard quality of life measures: the subjective experiences of living with inflammatory bowel disease.

Authors:  Barat J Wolfe; Fuschia M Sirois
Journal:  Qual Life Res       Date:  2008-06-03       Impact factor: 4.147

Review 4.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

5.  Quality of life and time perspective in inflammatory bowel disease patients.

Authors:  Vanessa Laguette; Themis Apostolidis; Lionel Dany; Nelly Bellon; Jean-Charles Grimaud; Marie-Claude Lagouanelle-Simeoni
Journal:  Qual Life Res       Date:  2013-04-08       Impact factor: 4.147

6.  The effectiveness of cognitive behavioral therapy on the quality of life of patients with inflammatory bowel disease: multi-center design and study protocol (KL!C- study).

Authors:  Floor Bennebroek Evertsz'; Claudi L H Bockting; Pieter C F Stokkers; Chris Hinnen; Robbert Sanderman; Mirjam A G Sprangers
Journal:  BMC Psychiatry       Date:  2012-12-14       Impact factor: 3.630

7.  An evil backstage manipulator: psychological factors correlated with health-related quality of life in Chinese patients with Crohn's disease.

Authors:  Song Liu; Jianan Ren; Zhiwu Hong; Xiaoting Li; Min Yao; Dongsheng Yan; Huajian Ren; Xiuwen Wu; Gefei Wang; Guosheng Gu; Qiuyuan Xia; Gang Han; Jieshou Li
Journal:  ScientificWorldJournal       Date:  2013-12-26

8.  Opioid use is associated with decreased quality of life in patients with Crohn's disease.

Authors:  David Sanford; Patrick Thornley; Anouar Teriaky; Nilesh Chande; James Gregor
Journal:  Saudi J Gastroenterol       Date:  2014 May-Jun       Impact factor: 2.485

9.  The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine.

Authors:  Aaron Yarlas; Linnette Yen; Paul Hodgkins
Journal:  Qual Life Res       Date:  2014-09-06       Impact factor: 4.147

10.  Long-term safety of vedolizumab for inflammatory bowel disease.

Authors:  Edward V Loftus; Brian G Feagan; Remo Panaccione; Jean-Frédéric Colombel; William J Sandborn; Bruce E Sands; Silvio Danese; Geert D'Haens; David T Rubin; Ira Shafran; Andrejus Parfionovas; Raquel Rogers; Richard A Lirio; Séverine Vermeire
Journal:  Aliment Pharmacol Ther       Date:  2020-09-02       Impact factor: 8.171

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.